Both Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Odonate Therapeutics Inc. (NASDAQ:ODT) are each other’s competitor in the Biotechnology industry. Thus the compare of their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Alexion Pharmaceuticals Inc. and Odonate Therapeutics Inc.

Profitability

Table 2 has Alexion Pharmaceuticals Inc. and Odonate Therapeutics Inc.’s return on assets, net margins and return on equity.

Liquidity

Alexion Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 4 and 3.6 respectively. The Current Ratio and Quick Ratio of its competitor Odonate Therapeutics Inc. are 9.6 and 9.6 respectively. Odonate Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Alexion Pharmaceuticals Inc.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Alexion Pharmaceuticals Inc. and Odonate Therapeutics Inc.

Alexion Pharmaceuticals Inc. has a 48.98% upside potential and a consensus target price of $160. Odonate Therapeutics Inc. on the other hand boasts of a $10 consensus target price and a -64.74% potential downside. The results provided earlier shows that Alexion Pharmaceuticals Inc. appears more favorable than Odonate Therapeutics Inc., based on analyst view.

Institutional & Insider Ownership

The shares of both Alexion Pharmaceuticals Inc. and Odonate Therapeutics Inc. are owned by institutional investors at 98.8% and 83.5% respectively. About 0.3% of Alexion Pharmaceuticals Inc.’s share are owned by insiders. Comparatively, Odonate Therapeutics Inc. has 0.1% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Alexion Pharmaceuticals Inc. was less bullish than Odonate Therapeutics Inc.

Summary

On 8 of the 10 factors Alexion Pharmaceuticals Inc. beats Odonate Therapeutics Inc.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.